INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $9 | -99.1% | 180 | -94.0% | 0.00% | – |
| Q3 2022 | $1,000 | -95.7% | 3,000 | -36.2% | 0.00% | -100.0% |
| Q2 2022 | $23,000 | -86.3% | 4,700 | -59.8% | 0.00% | -77.8% |
| Q1 2022 | $168,000 | -71.7% | 11,686 | -35.7% | 0.01% | -64.0% |
| Q4 2021 | $594,000 | +1112.2% | 18,186 | +439.2% | 0.02% | +1150.0% |
| Q3 2021 | $49,000 | +4.3% | 3,373 | -71.9% | 0.00% | 0.0% |
| Q2 2021 | $47,000 | -31.9% | 12,000 | +194.1% | 0.00% | -33.3% |
| Q1 2021 | $69,000 | -37.8% | 4,080 | -56.5% | 0.00% | -50.0% |
| Q4 2020 | $111,000 | -45.0% | 9,380 | -50.1% | 0.01% | -53.8% |
| Q3 2020 | $202,000 | +32.0% | 18,800 | +13.3% | 0.01% | +30.0% |
| Q2 2020 | $153,000 | +125.0% | 16,600 | +155.4% | 0.01% | +233.3% |
| Q1 2020 | $68,000 | -83.8% | 6,500 | -93.9% | 0.00% | -88.5% |
| Q4 2019 | $420,000 | +438.5% | 107,000 | +46.2% | 0.03% | +271.4% |
| Q3 2019 | $78,000 | +290.0% | 73,200 | +803.7% | 0.01% | +250.0% |
| Q2 2019 | $20,000 | -54.5% | 8,100 | +42.1% | 0.00% | -50.0% |
| Q1 2019 | $44,000 | -66.9% | 5,700 | -92.1% | 0.00% | -66.7% |
| Q4 2018 | $133,000 | -39.5% | 72,500 | +39.4% | 0.01% | -20.0% |
| Q3 2018 | $220,000 | -16.3% | 52,000 | -10.0% | 0.02% | -28.6% |
| Q2 2018 | $263,000 | -27.3% | 57,749 | +2.9% | 0.02% | -32.3% |
| Q1 2018 | $362,000 | +109.2% | 56,099 | +6.1% | 0.03% | +342.9% |
| Q4 2017 | $173,000 | -78.5% | 52,861 | -67.6% | 0.01% | -77.4% |
| Q3 2017 | $803,000 | +196.3% | 163,060 | +107.6% | 0.03% | +244.4% |
| Q2 2017 | $271,000 | -58.8% | 78,544 | -56.7% | 0.01% | -67.9% |
| Q1 2017 | $658,000 | +23.2% | 181,376 | +175.0% | 0.03% | +47.4% |
| Q4 2016 | $534,000 | -18.1% | 65,945 | -70.7% | 0.02% | -34.5% |
| Q3 2016 | $652,000 | +5.0% | 225,379 | +94.3% | 0.03% | -9.4% |
| Q2 2016 | $621,000 | +11.9% | 115,981 | +94.3% | 0.03% | -11.1% |
| Q1 2016 | $555,000 | +173.4% | 59,702 | +161.0% | 0.04% | +227.3% |
| Q4 2015 | $203,000 | – | 22,874 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |